Clinical Research Directory
Browse clinical research sites, groups, and studies.
Positron Emission Tomography/Computed Tomography (PET/CT) Imaging in Patients Diagnosed With a Glioma
Sponsor: Barbara Ann Karmanos Cancer Institute
Summary
The goal of this clinical trial is to evaluate Positron emission tomography/computed tomography (PET/CT) imaging with the radiotracer 1-(2-\[18F\]fluoroethyl)-l-tryptophan (\[18F\]FETrp) in patients diagnosed with a glioma. This study has 3 aims: * to assess if the \[18F\]FETrp PET/CT can outperform Magnetic Resonance Imaging (MRI) by providing a better treatment target volume in newly diagnosed Stage 4 glioma patients * better differentiate tumor progression from radiation induced MRI changes in post treatment stage 4 gliomas * by giving a drug that can inhibit a pathway to allow objective assessment of treatment effects in low grade gliomas
Official title: Tryptophan-kynurenine Pathway PET Imaging in Human Gliomas
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
61
Start Date
2026-09
Completion Date
2031-06-30
Last Updated
2026-07-30
Healthy Volunteers
No
Conditions
Interventions
Minocycline 200mg/day
Minocycline 200mg orally daily to start within 14 days of the first \[18F\]FETrp PET/CT and taken until the second \[18F\]FETrp PET/CT obtained 25-44 days after the start of the Minocycline in Arm 3
[18F]FETrp PET/CT
\[18F\]FETrp PET/CT used in all three arms
Locations (1)
Karmanos Cancer Institute
Detroit, Michigan, United States